US2014079695A1PendingUtilityA1

Preventive agent for vasculitis

39
Assignee: CHUGAI PHARMACEUTICAL CO LTDPriority: Dec 19, 2003Filed: Nov 22, 2013Published: Mar 20, 2014
Est. expiryDec 19, 2023(expired)· nominal 20-yr term from priority
Inventors:Norihiro NishimotoTadamitsu KishimotoHideko Nakahara
A61P 37/00A61P 37/02A61K 2039/505A61K 39/3955A61P 29/00C07K 2317/76C07K 16/2866C07K 2317/24A61P 9/00A61K 45/00A61K 39/395
39
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

To provide a preventive and/or therapeutic agent for vasculitis such as polyarteritis nodosa, the aortitis syndrome, and a vasculitis that is associated with immunological abnormalities, said agent comprising an interleukin-6 (IL-6) antagonist as an active ingredient.

Claims

exact text as granted — not AI-modified
1 . A method of manufacturing a pharmaceutical composition for the prevention and/or therapy of vasculitis, comprising mixing an interleukin-6 (IL-6) antagonist with a pharmaceutically acceptable excipient. 
     
     
         2 . A method of manufacturing a pharmaceutical composition for the prevention and/or therapy of vasculitis having resistance to steroids and/or immunosuppressants, comprising mixing an interleukin-6 (IL-6) antagonist with a pharmaceutically acceptable. 
     
     
         3 . The method according to  claim 1  wherein said vasculitis is polyarteritis nodosa. 
     
     
         4 . The method according to  claim 1  wherein said vasculitis is the aortitis syndrome. 
     
     
         5 . The method according to  claim 1  wherein said vasculitis is vasculitis associated with immunological abnormalities. 
     
     
         6 . The method according to  claim 1  wherein said IL-6 antagonist is an antibody against IL-6 receptor. 
     
     
         7 . The method according to  claim 6  wherein said antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor. 
     
     
         8 . The method according to  claim 6  wherein said antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor. 
     
     
         9 . The method according to  claim 6  wherein said antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor. 
     
     
         10 . The method according to  claim 6  wherein said antibody against IL-6 receptor is a recombinant antibody. 
     
     
         11 . The method according to  claim 8  wherein said monoclonal antibody against human IL-6 receptor is PM-1 antibody. 
     
     
         12 . The method according to  claim 9  wherein said monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody. 
     
     
         13 . The method according to  claim 6  wherein said antibody against IL-6 receptor is a chimeric antibody, a humanized antibody, or a human antibody. 
     
     
         14 . The method according to  claim 13  wherein said humanized antibody against IL-6 receptor is a humanized PM-1 antibody. 
     
     
         15 . A method of preventing and/or treating vasculitis comprising administering an interleukin-6 (IL-6) antagonist to a subject in need thereof. 
     
     
         16 . A method of preventing and/or treating vasculitis having resistance to steroids and/or immunosuppressants, comprising administering an interleukin-6 (IL-6) antagonist to a subject in need thereof. 
     
     
         17 . The method according to  claim 15  wherein said vasculitis is polyarteritis nodosa. 
     
     
         18 . The method according to  claim 15  wherein said vasculitis is the aortitis syndrome. 
     
     
         19 . The method according to  claim 15  wherein said vasculitis is vasculitis associated with immunological abnormalities. 
     
     
         20 . The method according to  claim 15  wherein said IL-6 antagonist is an antibody against IL-6 receptor. 
     
     
         21 . The method according to  claim 20  wherein said antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor. 
     
     
         22 . The method according to  claim 20  wherein said antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor. 
     
     
         23 . The method according to  claim 20  wherein said antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor. 
     
     
         24 . The method according to  claim 20  wherein said antibody against IL-6 receptor is a recombinant antibody. 
     
     
         25 . The method according to  claim 22  wherein said monoclonal antibody against human IL-6 receptor is PM-1 antibody. 
     
     
         26 . The method according to  claim 23  wherein said monoclonal antibody against mouse IL-6 receptor is MR1 antibody. 
     
     
         27 . The method according to  claim 20  wherein said antibody against IL-6 receptor is a chimeric antibody, humanized antibody, or a human antibody against IL-6 receptor. 
     
     
         28 . The method according to  claim 27  wherein said humanized antibody against IL-6 receptor is a humanized PM-1 antibody.

Join the waitlist — get patent alerts

Track US2014079695A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.